Author: Pourhassan, H; DeFor, T; Trottier, B; Dolan, M; Brunstein, C; Bejanyan, N; Ustun, C; Warlick, E D
Title: MDS disease characteristics, not donor source, predict hematopoietic stem cell transplant outcomes Cord-id: 97xah833 Document date: 2016_12_12
ID: 97xah833
Snippet: Myelodysplastic syndrome (MDS) is a heterogeneous group of hematological malignancies with considerably variable prognoses and curable only with hematopoietic cell transplantation (HCT). Few studies comparing MDS HCT outcomes between sibling and umbilical cord blood (UCB) donors exist. Using the University of Minnesota Blood and Marrow Transplant (BMT) database, we retrospectively analyzed HCT outcomes among 89 MDS patients undergoing either sibling or double UCB HCT in 2000–2013. We observed
Document: Myelodysplastic syndrome (MDS) is a heterogeneous group of hematological malignancies with considerably variable prognoses and curable only with hematopoietic cell transplantation (HCT). Few studies comparing MDS HCT outcomes between sibling and umbilical cord blood (UCB) donors exist. Using the University of Minnesota Blood and Marrow Transplant (BMT) database, we retrospectively analyzed HCT outcomes among 89 MDS patients undergoing either sibling or double UCB HCT in 2000–2013. We observed similar survival, relapse and non-relapse mortality between sibling and UCB donor sources. Relapse was increased in those with monosomal karyotype (P=0.04) and with reduced intensity conditioning (P<0.01). In summary, our data highlight similar MDS HCT outcomes regardless of donor source and support the use of UCB as an alternative donor when a sibling is unavailable.
Search related documents:
Co phrase search for related documents- acute gvhd and low incidence: 1, 2, 3, 4
- acute gvhd and ma conditioning: 1
- acute gvhd and ma regimen: 1
- ma conditioning and ma regimen: 1
Co phrase search for related documents, hyperlinks ordered by date